Research and Markets: Global Hodgkins Lymphoma Therapeutics Market 2014-2018: Bristol Myers Squibb, F. Hoffmann-La Roche, Merck & Co & Pfizer Dominate the Industry

Research and Markets (http://www.researchandmarkets.com/research/gtf8vh/global_hodgkins) has announced the addition of the "Global Hodgkins Lymphoma Therapeutics Market 2014-2018" report to their offering.

The Global Hodgkin's Lymphoma Therapeutics market will grow at a CAGR of 6.84 percent over the period 2013-2018.

There has been an increase in awareness of Hodgkin's lymphoma among patients and physicians. Enhanced patient and physician awareness is expected to lead to earlier disease diagnosis and treatment. The acceptability of Hodgkin's lymphoma drugs is expected to rise because of the increasing public awareness. Raising general awareness about Hodgkin's lymphoma has led to an increase in research funding and support for clinical and support services. For instance, September 15 is celebrated as WLAD by the LRF. The program was initiated to make people more aware about both Hodgkin's lymphoma and NHL in terms of symptom recognition, early diagnosis, and treatment.

According to the report the Global Hodgkin's Lymphoma Therapeutics market is driven by several factors. One of the main drivers in this market is the improved diagnostic techniques. Improved diagnostic techniques have led to the treatment of Hodgkin's lymphoma in an aggressive way and have driven revenue growth in a positive direction. Improvement in the diagnosis leads to the early detection and treatment of the disease.

Further, the report states that the Global Hodgkin's Lymphoma Therapeutics market is inhibited by some serious challenges. One of the main challenges is the high cost of Hodgkin's lymphoma treatment. Despite the numerous benefits, the high cost of treatment options hinders the acceptability among patients. Many patients do not have the required budget for investing in high-cost treatment options.

The Global Hodgkin's Lymphoma Therapeutics market can be divided into eight segments:

• Alkylating Antineoplastic Agents
• Antibiotic Antineoplastic Agents
• Antineoplastics Vinca Alkaloid Agents
• Podophyllotoxin Derivative Antineoplastic Agents
• Antimetabolite Antineoplastic Agents
• Anthracycline Antineoplastic Agents
• Antimicrotubular Antineoplastics
• Corticosteroids
  

Key Vendors

• Bristol Myers Squibb Co.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Pfizer Inc.

Other Prominent Vendors

• 4SC AG
• Actinium Pharmaceuticals Inc.
• Aeterna Zentaris Inc.
• Affimed Therapeutics AG
• Hospira Inc.
• Incyte Corp.
• Novartis AG
• Philogen S.p.A.
• Seattle Genetics Inc.
• Sigma-Tau Pharmaceuticals Inc.
• Stemline Therapeutics Inc.
• Teva Pharmaceutical Industries Ltd.

For more information visit http://www.researchandmarkets.com/research/gtf8vh/global_hodgkins